Company Overview - Lifecore Biomedical, Inc. is a fully integrated contract development and manufacturing organization (CDMO) specializing in the development, fill, and finish of sterile injectable pharmaceutical products [2] - The company has over 40 years of expertise in manufacturing premium, injectable-grade hyaluronic acid, serving global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories [2] Recent Developments - Lifecore hosted a virtual investor day where senior management discussed the company's business and future growth strategy [1] - The event was made accessible via a webcast, allowing investors to engage with the company's strategic direction [1]

Company Overview - Lifecore Biomedical Inc is a fully integrated contract development and manufacturing organization (CDMO) specializing in sterile injectable pharmaceutical products [3] - The company has over 40 years of expertise in manufacturing premium injectable-grade hyaluronic acid [3] - Lifecore serves global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories [3] Upcoming Event - Lifecore will host a virtual investor day on November 21 2024 from 8:00 - 9:30 am Eastern Time [1] - The event will feature discussions on the company's business and growth strategy by senior management [1] - The webcast will be available on Lifecore's investor relations website [2]

Core Viewpoint - Johnson Fistel, LLP is investigating potential breaches of fiduciary duties by directors and officers of Lifecore Biomedical, Inc. related to financial reporting issues and class action complaints against the company [1][4]. Group 1: Investigation Details - The investigation was initiated on March 20, 2024, following Lifecore's issuance of its Annual Report on Form 10-K/A for the year ended May 29, 2022, which included restatements of financial statements due to errors in capitalized interest calculations and inventory valuations [3]. - The restatements were necessary to correct inaccuracies in several financial statements that Lifecore had previously issued, which were deemed materially false and misleading [3][4]. - A class action complaint alleges that Lifecore's management made false statements regarding the company's business operations and failed to disclose deficiencies in internal controls over financial reporting [3]. Group 2: Allegations Against Lifecore - The allegations include that Lifecore maintained deficient internal controls, leading to inaccurate financial statements that required restatement [3]. - It is claimed that Lifecore's remediation efforts regarding these deficiencies were ineffective, impairing the company's ability to file periodic reports with the SEC in compliance with NASDAQ requirements [3]. - The company's financial position and prospects were allegedly overstated, resulting in materially false and misleading public statements [3].

Exhibit 10.1 LIFECORE BIOMEDICAL, INC. STOCK PURCHASE AGREEMENT This Stock Purchase Agreement ("Agreement") is made as of October 3, 2024 (the "Effective Date"), by and among Lifecore Biomedical, Inc., a Delaware corporation (the "Company"), and each of those persons and entities, severally and not jointly, listed as a Purchaser on the Schedule of Purchasers attached as Exhibit A hereto (the "Schedule of Purchasers"). Such persons and entities are hereinafter collectively referred to herein as "Purchasers" ...

CHASKA, Minn., Oct. 04, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. ("Lifecore"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced the closing of a $24.3 million private placement ("PIPE") of 5,928,775 shares of its common stock at a price of $4.10 per share. The investing group includes new and existing shareholders, and the company expects to use the proceeds for working capital, operations, and general corporate purposes. "We are very pleased to have ...

CHASKA, Minn., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) ("Lifecore"), a fully integrated contract development and manufacturing organization ("CDMO"), today announced that the company will participate at four upcoming industry events. Details of the company's activities at these events are as follows: Medical Aesthetic Injectable Summit 2024 Conference Date/Location: October 4-5, 2024, in Marbella, Spain Details: Darren Hieber, Lifecore's senior vice president of corporate ...

NEW YORK, Sept. 23, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lifecore Biomedical, Inc. (NASDAQ: LFCR) between October 7, 2020 and March 19, 2024, both dates inclusive (the "Class Period"), of the important September 27, 2024 lead plaintiff deadline. SO WHAT: If you purchased Lifecore securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arr ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Lifecore Biomedical, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on September 27, 2024 [1] Group 1: Class Action Details - Investors who purchased Lifecore securities between October 7, 2020, and March 19, 2024, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by the deadline [3] - The lawsuit alleges that Lifecore made false and misleading statements regarding its financial reporting and internal controls, leading to inaccurate financial statements that would need to be restated [5] Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions, highlighting its own achievements in this area [4] - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been recognized as a leader in the field of securities class action litigation [4]

Installation and Qualification Successfully Completed for Closed-System Filler for Pre-Filled Syringes, Vials, and Cartridges Offers State-of-the-Art Speed and Aseptic Isolation Required for Fill/Finish of Latest Sterile Injectable Pharmaceutical and Biopharmaceutical Products Current Capacity More than Doubles with New Filler CHASKA, Minn., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) ("Lifecore"), a fully integrated contract development and manufacturing organization ("CDMO" ...

NEW YORK, Sept. 17, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lifecore Biomedical, Inc. (NASDAQ: LFCR) between October 7, 2020 and March 19, 2024, both dates inclusive (the "Class Period"), of the important September 27, 2024 lead plaintiff deadline. So What: If you purchased Lifecore securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. ...